These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27120338)

  • 1. A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes.
    Janssen EM; Segal JB; Bridges JF
    Patient; 2016 Oct; 9(5):465-79. PubMed ID: 27120338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attribute Selection for a Discrete Choice Experiment Incorporating a Best-Worst Scaling Survey.
    Webb EJD; Meads D; Lynch Y; Judge S; Randall N; Goldbart J; Meredith S; Moulam L; Hess S; Murray J
    Value Health; 2021 Apr; 24(4):575-584. PubMed ID: 33840436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment.
    Mühlbacher AC; Sadler A; Juhnke C
    Eur J Health Econ; 2021 Apr; 22(3):425-443. PubMed ID: 33587221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Discrete-Choice Experiment (DCE) to Elicit Adolescent and Parent Preferences for Hypodontia Treatment.
    Barber S; Bekker H; Marti J; Pavitt S; Khambay B; Meads D
    Patient; 2019 Feb; 12(1):137-148. PubMed ID: 30367434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of discrete choice experiments to enhance stakeholder engagement as a strategy for advancing implementation: a systematic review.
    Salloum RG; Shenkman EA; Louviere JJ; Chambers DA
    Implement Sci; 2017 Nov; 12(1):140. PubMed ID: 29169397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.
    Seo J; Smith BD; Estey E; Voyard E; O' Donoghue B; Bridges JFP
    Curr Med Res Opin; 2018 Dec; 34(12):2031-2039. PubMed ID: 29565196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholder Engagement in Designing Attributes for a Discrete Choice Experiment With Policy Implications: An Example of 2 Swiss Studies on Healthcare Delivery.
    Föhn Z; Nicolet A; Marti J; Kaufmann C; Balthasar A
    Value Health; 2023 Jun; 26(6):925-933. PubMed ID: 36646277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies].
    Mühlbacher AC; Kaczynski A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patient preferences for diabetes care: A protocol for implementing a discrete choice experiment in Samoa.
    Rivara AC; Galárraga O; Selu M; Arorae M; Wang R; Faasalele-Savusa K; Rosen R; Hawley NL; Viali S
    PLoS One; 2023; 18(12):e0295845. PubMed ID: 38134044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Self-Reported Acceptability of Discrete Choice Experiment and Best-Worst Scaling: An Empirical Study in Patients with Type 2 Diabetes Mellitus.
    Li F; Liu S; Gu Y; Li S; Tao Y; Wei Y; Chen Y
    Patient Prefer Adherence; 2024; 18():1803-1813. PubMed ID: 39229369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.
    Peay HL; Hollin I; Fischer R; Bridges JF
    Clin Ther; 2014 May; 36(5):624-37. PubMed ID: 24852596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Outcomes of a Discrete Choice Experiment and Case 2 Best-Worst Scaling: An Application to Neuromuscular Disease Treatment.
    Soekhai V; Donkers B; Johansson JV; Jimenez-Moreno C; Pinto CA; de Wit GA; de Bekker-Grob E
    Patient; 2023 May; 16(3):239-253. PubMed ID: 36781628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments.
    Janssen EM; Hauber AB; Bridges JFP
    Value Health; 2018 Jan; 21(1):59-68. PubMed ID: 29304942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?
    Veldwijk J; Essers BA; Lambooij MS; Dirksen CD; Smit HA; de Wit GA
    Value Health; 2016; 19(2):202-9. PubMed ID: 27021754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative Development of a Discrete Choice Experiment for Physical Activity Interventions to Improve Knee Osteoarthritis.
    Pinto D; Danilovich MK; Hansen P; Finn DJ; Chang RW; Holl JL; Heinemann AW; Bockenholt U
    Arch Phys Med Rehabil; 2017 Jun; 98(6):1210-1216.e1. PubMed ID: 28034720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respondent Understanding in Discrete Choice Experiments: A Scoping Review.
    Pearce A; Harrison M; Watson V; Street DJ; Howard K; Bansback N; Bryan S
    Patient; 2021 Jan; 14(1):17-53. PubMed ID: 33141359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question.
    Mansfield C; Sutphin J; Boeri M
    Health Econ; 2020 Oct; 29(10):1307-1315. PubMed ID: 32627284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Do Members of the Duchenne and Becker Muscular Dystrophy Community Perceive a Discrete-Choice Experiment Incorporating Uncertain Treatment Benefit? An Application of Research as an Event.
    Bridges JFP; Tsai JH; Janssen E; Crossnohere NL; Fischer R; Peay H
    Patient; 2019 Apr; 12(2):247-257. PubMed ID: 30259384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.